For the nine patient samples in which drug effects were evaluated by cell numbers after the longest drug exposure, usually 3 weeks, a mean of 31%+/−6% (SE) of tumor cells remained after treatment with the Mirk kinase inhibitor EHT5372, a mean of 46%+/−10% remained after treatment with the elevated dosage of cisplatin, a mean of 38%+/−14% remained after treatment with RAD001, and a mean of 9%+/−2% of tumor cells remained after concurrent treatment with the Mirk kinase inhibitor and the mTOR inhibitor RAD001(Fig. 4A). This evidence concerns the gene MTOR and neoplasm.